Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara; Carson Norwood; Katherine Floyd; Lilin Lai; Meredith E. Davis-Gardner; William H. Hudson; Grace Mantus; Lindsay E. Nyhoff; Max W. Adelman; Rebecca Fineman; Shivan Patel; Rebecca Byram; Dumingu Nipuni Gomes; Garett Michael; Hayatu Abdullahi; Nour Beydoun; Bernadine Panganiban; Nina McNair; Kieffer Hellmeister; Jamila Pitts; Joy Winters; Jennifer Kleinhenz; Jacob Usher; James O'Keefe; Anne Piantadosi; Jesse Waggoner; Ahmed Babiker; David Stephens; Evan Anderson; Srilatha Edupuganti; Nadine Rouphael; Rafi Ahmed; Jens Wrammert; Mehul Suthar

About this item:

162 Views | 126 Downloads

Author Notes:

V.E., M.S., C.N., K.F., L.L., and M.D.G. contributed to the acquisition, analysis and interpretation of the data. W.H.H., G.M., L.E.N., M.W.A., R.F., S.P., R.B., D.N.G., G.M., H.A., N.B., B.P., N.M., K.H., J.P., J.W., J.K., J.U., J.B.O., A.P., J.J.W., and A.B. contributed to the acquisition, analysis, and interpretation of the data. S.E. served as the principal investigator of the clinical protocol for acquisition of patient samples and contributed to interpretation of the data. E.J.A. and N.R. contributed to the acquisition, analysis, and interpretation of the data. R.A., J.W., V.E., and M.S. contributed to the acquisition, analysis, and interpretation of the data as well as the conception and design of the work and writing of the manuscript.

We thank Jim Wilbur (Mesoscale Discovery) for providing reagents to perform the RBD-binding assays. The graphical abstract was created with Biorender.com. The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/South Africa/KRISP-K005325/2020, NR-54009, contributed by Alex Sigal and Tulio de Oliveira. We thank Natalie Thornburg, Clinton Paden, and Suxiang Tong for sequencing and analysis of the B.1.351 variant (CDC, Atlanta, GA).

The authors declare no competing interests.

Subjects:

Research Funding:

This work was supported in part by grants (P51 OD011132, 3U19AI057266-17S1 CCHI Immune Memory Supplement, U19AI090023, R01AI127799, R01AI148378, K99AI153736, 1UM1AI148576-01, 5R38AI140299-03, and UM1AI148684 to Emory University) from the National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (NIH), The Oliver S. and Jennie R. Donaldson Charitable Trust, the Emory Executive Vice President for Health Affairs Synergy Fund award, the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children’s Healthcare of Atlanta, COVID-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine, a Woodruff Health Sciences Center 2020 COVID-19 CURE Award, and the Vital Projects/Proteus funds.

Keywords:

Science & Technology
Life Sciences & Biomedicine
Microbiology
Parasitology
Virology
DOMAIN

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara, Emory University

Carson Norwood, Emory University

Katherine Floyd, Emory University

Lilin Lai, Emory University

Meredith E. Davis-Gardner, Emory University

William H. Hudson, Emory University

Grace Mantus, Emory University

Lindsay E. Nyhoff, Emory University

Max W. Adelman, Emory University

Rebecca Fineman, Emory University

Shivan Patel, Emory University

Rebecca Byram, Emory University

Dumingu Nipuni Gomes, Emory University

Garett Michael, Emory University

Hayatu Abdullahi, Emory University

Nour Beydoun, Emory University

Bernadine Panganiban, Emory University

Nina McNair, Emory University

Kieffer Hellmeister, Emory University

Jamila Pitts, Emory University

Joy Winters, Emory University

Jennifer Kleinhenz, Emory University

Jacob Usher, Emory University

James O'Keefe, Emory University

Anne Piantadosi, Emory University

Jesse Waggoner, Emory University

Ahmed Babiker, Emory University

David Stephens, Emory University

Evan Anderson, Emory University

Srilatha Edupuganti, Emory University

Nadine Rouphael, Emory University

Rafi Ahmed, Emory University

Jens Wrammert, Emory University

Mehul Suthar, Emory University

Show all authors Show less authors

Tools:

Journal Title:

CELL HOST & MICROBE

Volume:

Volume 29, Number 4

Publisher:

CELL PRESS | 2021-04-14, Pages 516-+

Type of Work:

Article | Final Publisher PDF

Permanent URL:

https://pid.emory.edu/ark:/25593/vkvpc

Publisher DOI:

http://doi.org/10.1016/j.chom.2021.03.009

Abstract:

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

Copyright information:

Export to EndNote

Undergraduate

Community

Graduate

Libraries

Library Tools

Resources

Resources

About this item:

Author Notes:

Subjects:

Research Funding:

Keywords:

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Tools:

Abstract:

Copyright information: